1053058-99-3

Basic information

• Product Name: 3,4-DiMethoxybenzaMidoxiMe, 97%
• Synonyms: 3,4-DiMethoxybenzaMidoxiMe, 97%
• CAS NO: 1053058-99-3
• Molecular Formula: C₉H₁₂N₂O₃
• Molecular Weight: 196.20318
• Mol File: 1053058-99-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,4-DiMethoxybenzaMidoxiMe, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DiMethoxybenzaMidoxiMe, 97%(1053058-99-3)
• EPA Substance Registry System: 3,4-DiMethoxybenzaMidoxiMe, 97%(1053058-99-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1053058-99-3(Hazardous Substances Data)

Upstream product

• 2024-83-1 veratronitrile 

Downstream Products

• 94297-19-5 [3-(3,4-dimethoxy-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-diethyl-amine 
• 91066-47-6 5-chloromethyl-3-(3,4-dimethoxy-phenyl)-[1,2,4]oxadiazole 
• 26904-02-9 3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5(4H)-one 
• 95515-26-7 N-(3-chloro-propionyloxy)-3,4-dimethoxy-benzamidine 
• 95709-23-2 N-chloroacetoxy-3,4-dimethoxy-benzamidine 

Relevant articles and documents

1,2,4-oxadiazole-3,4-dihydroquinoline type compound as well as preparation method and application thereof

The invention discloses a 1,2,4-oxadiazole-3,4-dihydroquinoline type compound as well as a preparation method and an application thereof. The preparation method comprises the following steps: placingsubstituted benzonitrile, hydroxylamine hydrochloride an

Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator

To explore novel cardiac myosin activator, a series of diphenylalkyl substituted 1,3,4-oxadiazoles and 1,2,4-oxadiazoles have been prepared and tested for cardiac myosin ATPase activation in vitro. In all cases, three carbon spacer between the oxadiazole core and one of the phenyl ring was considered crucial. In case of 1,3,4-oxadiazole, zero to two carbon spacer between oxadiazole core and other phenyl ring are favorable. Phenyl ring can be replaced by cyclohexyl moiety. In case of 1,2,4-oxadiazole, zero or one carbon spacer between the oxadiazole and other phenyl ring are favorable. Introduction of hydrogen bonding donor (NH) group at the 2nd position of the 1,3,4-oxadiazole enhances the activity. Substitutions on either of the phenyl rings or change of phenyl ring to other heterocycle are not tolerated for both the oxadiazoles. The prepared oxadiazoles showed selective activation for cardiac muscle over smooth and skeleton muscles.